We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+49.01%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.43B
AUM Growth
-$263M
(-15%)
Cap. Flow
-$141M
Cap. Flow
% of AUM
-9.8%
Top 10 Holdings %
Top 10 Hldgs %
54.7%
Holding
66
New
3
Increased
9
Reduced
40
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurogene
NGNE
|
+$13.2M |
| 2 |
CBLL
CeriBell Inc
CBLL
|
+$11.9M |
| 3 |
RAPT
RAPT Therapeutics
RAPT
|
+$9.48M |
| 4 |
LivaNova
LIVN
|
+$8.64M |
| 5 |
SLN
Silence Therapeutics
SLN
|
+$6.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AUGX
Augmedix, Inc. Common Stock
AUGX
|
+$38.5M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$36.1M |
| 3 |
Scholar Rock
SRRK
|
+$22.4M |
| 4 |
Kymera Therapeutics
KYMR
|
+$13.2M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RPTX
51
DELISTED
Repare Therapeutics
RPTX
| $2.51M | 0.17% |
1,916,089
-26,466
| -1% | -$78.8K |
|
52
Insulet
PODD
$11.4B
| $2.5M | 0.17% |
+9,559
| New | +$2.41M |
|
53
Solid Biosciences
SLDB
$858M
| $2.46M | 0.17% |
+615,246
| New | +$3.38M |
|
|
BOLD
54
Boundless Bio
BOLD
$55.7M
| $2.15M | 0.15% |
740,204
-283,344
| -28% | -$826K |
|
|
LVTX
55
DELISTED
LAVA Therapeutics
LVTX
| $1.97M | 0.14% |
2,074,372
| – | – |
|
|
ACHL
56
DELISTED
Achilles Therapeutics
ACHL
| $1.83M | 0.13% |
1,608,089
| – | – |
|
57
Xeris Biopharma Holdings
XERS
$1.52B
| $1.53M | 0.11% |
451,099
-595,488
| -57% | -$1.92M |
|
58
Invivyd
IVVD
$219M
| $1.33M | 0.09% |
3,012,254
-53,460
| -2% | -$41.6K |
|
|
KLRS
59
Kalaris Therapeutics
KLRS
$104M
| $801K | 0.06% |
82,955
| – | – |
|
|
ADAP
60
DELISTED
Adaptimmune Therapeutics
ADAP
| $385K | 0.03% |
715,607
| – | – |
|
|
VTYX
61
DELISTED
Ventyx Biosciences
VTYX
| $272K | 0.02% |
124,178
-1,983,037
| -94% | -$4.49M |
|
|
HOOK
62
DELISTED
HOOKIPA Pharma
HOOK
| $214K | 0.01% |
106,376
| – | – |
|
63
Cabaletta Bio
CABA
$461M
| – | – |
-442,826
| Closed | -$2.09M |
|
|
CTLT
64
DELISTED
CATALENT, INC.
CTLT
| – | – |
-595,570
| Closed | -$36.1M |
|
|
GRTS
65
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| – | – |
-4,920,178
| Closed | -$2.85M |
|
|
AUGX
66
DELISTED
Augmedix, Inc. Common Stock
AUGX
| – | – |
-16,380,327
| Closed | -$38.5M |
|
Similar funds
ORI
KP
FMI
FCM
SCM
PP
AM
BFO
Redmile Group's Q4 2024 Portfolio in Review
As of Q4 2024, Redmile Group held 66 positions worth $1.43B, down 15% from $1.7B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Redmile Group withdrew a net $141M in Q4 2024, closing 4 positions and reducing 40 holdings. Its most notable exit was Augmedix, Inc. Common Stock, an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Industrials.
Against the trend, Redmile Group opened a new position in CeriBell Inc worth $11.3M.
- Redmile Group's largest Q4 2024 buy was CeriBell Inc: 435,239 shares worth $11.3M.
- Redmile Group added most to Neurogene in Q4 2024, an estimated $13.2M increase.
- Redmile Group's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $22.4M.
- Redmile Group fully exited Augmedix, Inc. Common Stock in Q4 2024, selling an estimated $38.5M.
- Redmile Group's ten largest holdings make up 55% of its $1.43B portfolio in Q4 2024.
- Redmile Group opened 3 new positions and closed 4 in Q4 2024.
- Redmile Group's portfolio value fell 15% quarter-over-quarter to $1.43B.
Based on Redmile Group's 13F filing for Q4 2024, filed 14 Feb 2025.